Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immune Reconstitution Inflammatory Syndrome Associated with Biologic Therapy

Immune Reconstitution Inflammatory Syndrome Associated with Biologic Therapy The use of biologics in the treatment of autoimmune disease, cancer, and other immune conditions has revolutionized medical care in these areas. However, there are drawbacks to the use of these medications including increased susceptibility to opportunistic infections. One unforeseen risk once opportunistic infection has occurred with biologic use is the onset of immune reconstitution inflammatory syndrome (IRIS) upon drug withdrawal. Although originally described in human immunodeficiency virus (HIV) patients receiving highly active antiretroviral therapy, it has become clear that IRIS may occur when recovery of immune function follows opportunistic infection in the setting of previous immune compromise/suppression. In this review, we draw attention to this potential pitfall on the use of biologic drugs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Allergy and Asthma Reports Springer Journals

Loading next page...
 
/lp/springer-journals/immune-reconstitution-inflammatory-syndrome-associated-with-biologic-OwH2ElsmrE

References (89)

Publisher
Springer Journals
Copyright
Copyright © Springer Science+Business Media New York 2014
Subject
Medicine & Public Health; Allergology
ISSN
1529-7322
eISSN
1534-6315
DOI
10.1007/s11882-014-0499-4
pmid
25504263
Publisher site
See Article on Publisher Site

Abstract

The use of biologics in the treatment of autoimmune disease, cancer, and other immune conditions has revolutionized medical care in these areas. However, there are drawbacks to the use of these medications including increased susceptibility to opportunistic infections. One unforeseen risk once opportunistic infection has occurred with biologic use is the onset of immune reconstitution inflammatory syndrome (IRIS) upon drug withdrawal. Although originally described in human immunodeficiency virus (HIV) patients receiving highly active antiretroviral therapy, it has become clear that IRIS may occur when recovery of immune function follows opportunistic infection in the setting of previous immune compromise/suppression. In this review, we draw attention to this potential pitfall on the use of biologic drugs.

Journal

Current Allergy and Asthma ReportsSpringer Journals

Published: Feb 1, 2015

Keywords: Immune reconstitution inflammatory syndrome; Monoclonal antibodies; JAK inhibitors; Biologics; Autoimmunity; Progressive multifocal leukoencephalopathy

There are no references for this article.